Through
10/10
The approval of CAR T cell therapy ushered in a new era for cancer treatment.
Penn’s infrastructure in both supporting clinical research and forging commercial partnerships smooths the way from idea to approval.
Kara Maxwell, director of the Men & BRCA Program at the Basser Center, is bridging the knowledge gap about how BRCA mutations affect men.
A new technique based on special cell-penetrating peptides promises advantages over current methods for editing the genomes of primary cells, such as patients’ T cells.
Since 2017, the FDA approved more than two dozen new therapies with roots at Penn Medicine—almost half of which are first-in-class for their indications.
In a student-led effort, the School of Dental Medicine hosted the Oral Cancer Walk & 5K. The event has been an annual tradition since 2009, offering both a community celebration and a venue for discussing oral cancer prevention and detection.
Using a Penn-designed neural network called PocketMiner, a Penn Medicine research team has identified hidden protein pockets that can provide new opportunities for cancer drugs to bind to.
A new Penn Medicine preclinical study finds that a new simultaneous “knockout” of two inflammatory regulators boosted T cell expansion to attach solid tumors.
Since 2012, the Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center has been advancing lifesaving therapies and raising awareness of the risks faced by individuals with BRCA gene mutations.
Penn researchers are developing new ways to detect and “intercept” cancer from every angle, including basic science to understand the molecular changes that lead to cancer and developing new methods for finding it.
Drew Weissman of the Perelman School of Medicine is supportive of findings about a pancreatic cancer vaccine, though he says larger studies are needed to determine effectiveness.
FULL STORY →
Robert Vonderheide and Constantinos Koumenis of the Perelman School of Medicine discuss the major advancements occurring in cancer surgery and cancer radiation, two fundamental tools of cancer treatment.
FULL STORY →
Robert Vonderheide of the Perelman School of Medicine says that a combined immunotherapy-vaccine approach could be a game changer for melanoma patients.
FULL STORY →
According to Robert Vonderheide of the Perelman School of Medicine, the pandemic proved that mRNA vaccines could be used safely and developed quickly.
FULL STORY →
Carl June of the Perelman School of Medicine comments on the success of a new study using CAR-T cell therapy to combat tumors in children with a rare kind of cancer.
FULL STORY →
A preclinical study by researchers at the Perelman School of Medicine is using a novel “one-two punch” strategy to assist T cells in attacking solid tumors.
FULL STORY →